GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Pirtobrutinib tablets (Jaypirca)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Pirtobrutinib tablets (Jaypirca) - selected U.S. label sections

Product / population
Adult JAYPIRCA oral tablets.
Renal method
eGFR; label reports mL/min
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Official

Pirtobrutinib tablets (Jaypirca) - selected U.S. label sections

Open original reference

U.S. product labeling / DailyMed · Adult JAYPIRCA oral tablets.

Renal method: eGFR; label reports mL/min
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Severe renal impairment - dose reduction

For eGFR 15-29 mL/min, reduce a current 200 mg once-daily dose to 100 mg once daily. For other current doses, reduce by 50 mg; discontinue if the current dose is already 50 mg once daily. At eGFR 30-89, no renal dose adjustment is recommended.

RDM32-pirtobrutinib-jaypirca-1 · Source locator: 2.3; 8.6

Limit

Concomitant CYP3A inhibitors and inducers have separate modification rules. This renal table does not authorize combining adjustments by simple arithmetic or extrapolating to dialysis.

RDM32-pirtobrutinib-jaypirca-2 · Source locator: 2.4; 2.5; 7; 8.6

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd551845-0878-49a4-860f-839b83f6b801
Retrieved
2026-09-05
DailyMed Set ID
bd551845-0878-49a4-860f-839b83f6b801
Renal-function method
eGFR; label reports mL/min
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
2d5a643980c624a90c2c9143fcf465e87b1bcd7d059d682ecd9f256f0340507d

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=pirtobrutinib-jaypirca&s1=RDM32-label-pirtobrutinib-jaypirca&h1=5479b2359cad0af835e3473f0003601bbf57485aae1f91f53ae930cbbdff9ba8